Gene Therapy Trial for Rare Mitochondrial Blindness Disease Halted Early
A Phase 1/2 trial of NFS-02 gene therapy for LHON-associated vision loss was terminated before completion, raising questions about mitochondrial gene therapy.
Summary
Leber's Hereditary Optic Neuropathy (LHON) is a rare mitochondrial disease causing sudden, severe vision loss, typically in young adults. It is caused by mutations in mitochondrial DNA, most commonly in the ND4 gene, but also in ND1. Neurophth Therapeutics launched a Phase 1/2 clinical trial testing NFS-02, a gene therapy delivered via a single injection into the eye, targeting patients with the less common G3460A mutation in the ND1 gene. Adults aged 18 to 75 with confirmed ND1-related LHON and vision loss lasting between 6 months and 10 years were eligible. The trial aimed to assess safety and early signs of efficacy. However, the trial was terminated before completion, leaving unanswered questions about whether this approach could restore or preserve vision in this underserved patient population.
Detailed Summary
Leber's Hereditary Optic Neuropathy is a devastating mitochondrial disease that strips patients, often young men, of central vision rapidly and permanently. While no widely approved curative treatment exists for most LHON subtypes, gene therapy has emerged as one of the most promising avenues, with earlier work on the more common ND4 mutation generating significant scientific excitement. This trial sought to extend that hope to patients with the rarer G3460A ND1 mutation, a group that has received comparatively little therapeutic attention.
The study was a Phase 1/2 trial sponsored by Neurophth Therapeutics, enrolling adults aged 18 to 75 diagnosed with LHON due to the mitochondrial ND1 G3460A mutation. Participants had experienced vision loss for more than 6 months but less than 10 years, a window considered potentially responsive to gene therapy. Each subject received a single unilateral intravitreal injection of NFS-02, a gene therapy vector designed to deliver a functional copy of the ND1 gene directly to retinal cells.
The primary goals were evaluating safety, tolerability, and preliminary efficacy. No results from this trial have been publicly disclosed, as the study was terminated prior to completion. The reasons for termination are not specified in the available registry entry, which may reflect regulatory, safety, business, or enrollment challenges.
The termination is notable in the context of a competitive LHON gene therapy landscape. Approved or advanced therapies for ND4-LHON, such as lenadogene nolparvovec, have demonstrated the feasibility of the intravitreal gene delivery approach. Whether NFS-02 failed to replicate that promise for ND1 patients, or whether external factors drove the decision, remains unknown.
For clinicians managing LHON patients with ND1 mutations, this outcome underscores the continued unmet need. The absence of disclosed results limits any clinical translation, and the field awaits further disclosure or successor trials.
Key Findings
- NFS-02 gene therapy trial for ND1-mutation LHON was terminated before completion with no results disclosed.
- Trial targeted adults with G3460A mitochondrial mutation and vision loss lasting 6 months to 10 years.
- Delivery method was a single intravitreal injection, consistent with approaches used in ND4-LHON gene therapy.
- ND1-LHON remains an area of critical unmet need with no approved gene therapy available.
- Reasons for early termination are undisclosed, limiting lessons for future mitochondrial gene therapy development.
Methodology
This was a Phase 1/2, single-arm, open-label trial using unilateral intravitreal injection of NFS-02 in adults aged 18–75 with genetically confirmed G3460A ND1-LHON and vision loss duration between 6 months and 10 years. Primary endpoints included safety, tolerability, and preliminary efficacy. The trial was terminated prior to completion, and no results data are available in the registry.
Study Limitations
This summary is based on the abstract and clinical trial registry entry only, as no full results or publications are available. The reasons for trial termination are undisclosed, making it impossible to determine whether safety signals, efficacy failure, enrollment difficulties, or business decisions drove the outcome. Absence of results data means no conclusions can be drawn about NFS-02's actual safety or efficacy profile.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.